Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128890/
https://www.ncbi.nlm.nih.gov/pubmed/21747882
http://dx.doi.org/10.5045/kjh.2011.46.2.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128890/
https://www.ncbi.nlm.nih.gov/pubmed/21747882
http://dx.doi.org/10.5045/kjh.2011.46.2.103

Ejemplares similares